PD-1/PD-L1 blockade therapy with atezolizumab: a new paradigm in the treatment of non-small cell lung cancer (NSCLC)

PD-1/PD-L1 blockade therapy with atezolizumab: a new paradigm in the treatment of non-small cell lung cancer (NSCLC)

Abstract Now, platinum-based chemotherapy is used as the first-line treatment for advanced non-small cell lung cancer (NSCLC). Interestingly, a combination of immune checkpoint inhibitors, such as mepolizumab, with other targeted therapies and chemotherapy help to make a significant improvement. Ate...

Full description

Saved in:
Bibliographic Details
Main Authors: Samaneh Moradi, Pedram Sarikhani, Rafid Jihad Albadr, Waam Mohammed Taher, Mariem Alwan, Mahmood Jasem Jawad, Hiba Mushtaq, Niyousha Vakilzadehian
Format: Article
Language:English
Published: Springer 2025-03-01
Series:Discover Oncology
Subjects:
NSCLC
Atezolizumab
Immunotherapy
Chemotherapy
Clinic
Online Access:https://doi.org/10.1007/s12672-025-02076-3
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1007/s12672-025-02076-3

Similar Items